ABSTRACT
Hereditary coproporphyria (HCP) is caused by a partial deficiency of coproporphyrinogen oxidase during heme biosynthesis. Givosiran is approved for the treatment of acute hepatic porphyria. We herein report the case of a 47-year-old woman with HCP. Monthly givosiran administration improved her subjective symptoms and reduced her δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels to the normal range. However, givosiran was discontinued after six months due to a decreased renal function. The patient's ALA and PBG levels remained within the normal ranges, and her HCP-related symptoms resolved more than 2 years after the discontinuation of givosiran.
ABSTRACT
Myxedema coma is a rare endocrine emergency resulting from the decompensation of severe hypothyroidism, which is associated with a high mortality rate. It is characterized by the deterioration of mental status, hypothermia, hypotension, hyponatremia, and hypoventilation. Early disease diagnosis and advancements in intensive supportive care have reduced the mortality rate. Besides intensive supportive care, appropriate management of the underlying thyroid hormone deficiency is essential. However, as the disease is rare and unrecognized, evidence-based treatment of myxedema has not yet been established in many countries. An 84-year-old Japanese man with a history of Hashimoto's thyroiditis was referred to our hospital. On arrival, conscious disturbance, hypothermia, hypotension, and hypoventilation were observed. He had discontinued thyroid hormone replacement therapy for a year. He was diagnosed with myxedema coma. Immediately, he received intensive supportive care and a combination therapy of 200 µg levothyroxine and 50 µg liothyronine until the fifth hospital day. Subsequently, monotherapy with levothyroxine was continued at a dose of 150 µg daily. The thyroid hormone level reached the normal range a few days later, and cardiovascular disease did not develop during hospitalization. This case demonstrated the efficacy of the combination of levothyroxine and liothyronine in treating myxedema coma.
Subject(s)
Coma/drug therapy , Myxedema/drug therapy , Thyroxine/therapeutic use , Triiodothyronine/therapeutic use , Aged, 80 and over , Drug Therapy, Combination , Hashimoto Disease/drug therapy , Humans , Male , Treatment OutcomeABSTRACT
The molecular mechanism involved in the exocytosis of arginine vasopressin (AVP) is not fully known. Rabphilin-3A has been suggested as a novel autoantigen in infundibulo-neurohypophysitis (LINH), which leads to central diabetes insipidus through insufficient secretion of AVP. However, the role of rabphilin-3A in the pathogenesis of LINH remains unclear. Thus, the aim of the present study was to identify proteins binding rabphilin-3A in the posterior pituitary. Using glutathione S-transferase (GST)-pulldown assays and proteomic analyses, cullin-associated NEDD8-dissociated protein 1 (CAND1) was identified as a rabphilin-3A-binding protein in the posterior pituitary. Co-immunoprecipitation assays indicated that CAND1 interacted endogenously with rabphilin-3A. In addition, immunohistochemistry experiments showed that CAND1 immunoreactivity was detected mainly in the posterior pituitary, intermediate lobe, and the supraoptic nucleus in the hypothalamus, and less in the anterior lobe, partially co-localizing with rabphilin-3A. Overexpression of CAND1 resulted in deubiquitylation of rabphilin-3A in PC12 cells. Moreover, overexpression of CAND1 in PC12 cells co-transfected with AVP enhanced both basal and KCl-stimulated AVP secretion. The findings indicate that CAND1 inhibits the ubiquitylation of rabphilin-3A and positively regulates AVP secretion. These data shed light on a novel potential mechanism involving rabphilin-3A in AVP secretion, and suggest a new role of CAND1 as a regulator of hormone or neurotransmitter secretion.
Subject(s)
Adaptor Proteins, Signal Transducing/metabolism , Arginine Vasopressin/metabolism , Deubiquitinating Enzymes/metabolism , Nerve Tissue Proteins/metabolism , Pituitary Gland, Posterior/metabolism , Transcription Factors/metabolism , Vesicular Transport Proteins/metabolism , Animals , Deubiquitinating Enzymes/genetics , PC12 Cells , Rats , Rats, Sprague-Dawley , Transcription Factors/genetics , Rabphilin-3AABSTRACT
Autoimmune hypophysitis (AH) is thought to be an autoimmune disease characterized by lymphocytic infiltration of the pituitary gland. Among AH pathologies, lymphocytic infundibulo-neurohypophysitis (LINH) involves infiltration of the neurohypophysis and/or the hypothalamic infundibulum, causing central diabetes insipidus resulting from insufficiency of arginine vasopressin secretion. The pathophysiological and pathogenetic mechanisms underlying LINH are largely unknown. Clinically, differentiating LINH from other pituitary diseases accompanied by mass lesions, including tumours, has often been difficult, because of similar clinical manifestations. We recently reported that rabphilin-3A is an autoantigen and that anti-rabphilin-3A antibodies constitute a possible diagnostic marker for LINH. However, the involvement of rabphilin-3A in the pathogenesis of LINH remains to be elucidated. This study was undertaken to explore the role of rabphilin-3A in lymphocytic neurohypophysitis and to investigate the mechanism. We found that immunization of mice with rabphilin-3A led to neurohypophysitis. Lymphocytic infiltration was observed in the neurohypophysis and supraoptic nucleus 1 month after the first immunization. Mice immunized with rabphilin-3A showed an increase in the volume of urine that was hypotonic as compared with control mice. Administration of a cocktail of monoclonal anti-rabphilin-3A antibodies did not induce neurohypophysitis. However, abatacept, which is a chimeric protein that suppresses T-cell activation, decreased the number of T cells specific for rabphilin-3A in peripheral blood mononuclear cells (PBMCs). It ameliorated lymphocytic infiltration of CD3+ T cells in the neurohypophysis of mice that had been immunized with rabphilin-3A. Additionally, there was a linear association between the number of T cells specific for rabphilin-3A in PBMCs and the number of CD3+ T cells infiltrating the neurohypophysis. In conclusion, we suggest that rabphilin-3A is a pathogenic antigen, and that T cells specific for rabphilin-3A are involved in the pathogenesis of neurohypophysitis in mice. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Subject(s)
Adaptor Proteins, Signal Transducing , Autoimmune Hypophysitis/chemically induced , Autoimmunity , Nerve Tissue Proteins , Pituitary Gland, Posterior/metabolism , Vesicular Transport Proteins , Abatacept/administration & dosage , Animals , Antibodies, Monoclonal/administration & dosage , Autoimmune Hypophysitis/immunology , Autoimmune Hypophysitis/metabolism , Autoimmune Hypophysitis/prevention & control , Autoimmunity/drug effects , Disease Models, Animal , Female , Immunosuppressive Agents/administration & dosage , Mice , Pituitary Gland, Posterior/drug effects , Pituitary Gland, Posterior/immunology , Pituitary Gland, Posterior/pathology , Supraoptic Nucleus/immunology , Supraoptic Nucleus/metabolism , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , Urination , Rabphilin-3AABSTRACT
Arginine vasopressin (AVP) is secreted via exocytosis; however, the precise molecular mechanism underlying the exocytosis of AVP remains to be elucidated. To better understand the mechanisms of AVP secretion, in our study we have identified proteins that bind with a 25 kDa synaptosomal-associated protein (SNAP25). SNAP25 plays a crucial role in exocytosis, in the posterior pituitary. Embryonic stem (ES) cell-derived AVP neurons were established to investigate the functions of the identified proteins. Using glutathione S-transferase (GST)-pulldown assays and proteomic analyses, we identified tomosyn-1 (syntaxin-binding protein 5) as a SNAP25-binding protein in the posterior pituitary. Coimmunoprecipitation assays indicated that tomosyn formed N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complexes with SNAP25 and syntaxin1. Immunohistochemistry showed that tomosyn localized to the posterior pituitary. Mouse ES cells self-differentiated into AVP neurons (mES-AVP) that expressed tomosyn and two transmembrane SNARE proteins, including SNAP25 and syntaxin1. KCl increased AVP secretion in mES-AVP, and overexpression of tomosyn-1 reduced KCl-stimulated AVP secretion. Downregulation of tomosyn-1 with siRNA increased KCl-stimulated AVP secretion. These results suggested that tomosyn-1 negatively regulated AVP secretion in mES-AVP and further suggest the possibility of using mES-AVP culture systems to evaluate the role of synaptic proteins from AVP neurons.
Subject(s)
Arginine Vasopressin/metabolism , Mouse Embryonic Stem Cells/cytology , Nerve Tissue Proteins/metabolism , Neurogenesis , Neurons/cytology , R-SNARE Proteins/metabolism , Animals , Cell Line , Male , Mice , Mouse Embryonic Stem Cells/metabolism , Nerve Tissue Proteins/analysis , Neurons/metabolism , Pituitary Gland, Posterior/metabolism , Pituitary Gland, Posterior/ultrastructure , Protein Binding , Qa-SNARE Proteins/metabolism , R-SNARE Proteins/analysis , Rats, Sprague-Dawley , Synaptosomal-Associated Protein 25/metabolismABSTRACT
Hyponatremia is the most common clinical electrolyte disorder. Once thought to be asymptomatic in response to adaptation by the brain, recent evidence suggests that chronic hyponatremia may be linked to attention deficits, gait disturbances, risk of falls, and cognitive impairments. Such neurologic defects are associated with a reduction in quality of life and may be a significant cause of mortality. However, because underlying diseases such as adrenal insufficiency, heart failure, liver cirrhosis, and cancer may also affect brain function, the contribution of hyponatremia alone to neurologic manifestations and the underlying mechanisms remain unclear. Using a syndrome of inappropriate secretion of antidiuretic hormone rat model, we show here that sustained reduction of serum sodium ion concentration induced gait disturbances; facilitated the extinction of a contextual fear memory; caused cognitive impairment in a novel object recognition test; and impaired long-term potentiation at hippocampal CA3-CA1 synapses. In vivo microdialysis revealed an elevated extracellular glutamate concentration in the hippocampus of chronically hyponatremic rats. A sustained low extracellular sodium ion concentration also decreased glutamate uptake by primary astrocyte cultures, suggesting an underlying mechanism of impaired long-term potentiation. Furthermore, gait and memory performances of corrected hyponatremic rats were equivalent to those of control rats. Thus, these results suggest chronic hyponatremia in humans may cause gait disturbance and cognitive impairment, but these abnormalities are reversible and careful correction of this condition may improve quality of life and reduce mortality.
Subject(s)
Gait Disorders, Neurologic/etiology , Hyponatremia/complications , Inappropriate ADH Syndrome/physiopathology , Memory Disorders/etiology , Animals , Astrocytes/drug effects , Astrocytes/metabolism , CA1 Region, Hippocampal/physiopathology , CA3 Region, Hippocampal/physiopathology , Cells, Cultured , Chronic Disease , Cognition Disorders/blood , Cognition Disorders/etiology , Disease Models, Animal , Fear/physiology , Gait Disorders, Neurologic/blood , Glutamic Acid/metabolism , Hyponatremia/blood , Hyponatremia/psychology , Inappropriate ADH Syndrome/complications , Inappropriate ADH Syndrome/psychology , Male , Memory Disorders/blood , Microdialysis , Neuronal Plasticity , Rats , Rats, Sprague-Dawley , Sodium/blood , Sodium/pharmacology , Synapses/physiologyABSTRACT
CONTEXT: Central diabetes insipidus (CDI) can be caused by several diseases, but in about half of the patients the etiological diagnosis remains unknown. Lymphocytic infundibulo-neurohypophysitis (LINH) is an increasingly recognized entity among cases of idiopathic CDI; however, the differential diagnosis from other pituitary diseases including tumors can be difficult because of similar clinical and radiological manifestations. The definite diagnosis of LINH requires invasive pituitary biopsy. OBJECTIVE: The study was designed to identify the autoantigen(s) in LINH and thus develop a diagnostic test based on serum autoantibodies. DESIGN: Rat posterior pituitary lysate was immunoprecipitated with IgGs purified from the sera of patients with LINH or control subjects. The immunoprecipitates were subjected to liquid chromatography-tandem mass spectrometry to screen for pituitary autoantigens of LINH. Subsequently, we made recombinant proteins of candidate autoantigens and analyzed autoantibodies in serum by Western blotting. RESULTS: Rabphilin-3A proved to be the most diagnostically useful autoantigen. Anti-rabphilin-3A antibodies were detected in 22 of the 29 (76%) patients (including 4 of the 4 biopsy-proven samples) with LINH and 2 of 18 (11.1%) patients with biopsy-proven lymphocytic adeno-hypophysitis. In contrast, these antibodies were absent in patients with biopsy-proven sellar/suprasellar masses without lymphocytic hypophysitis (n = 34), including 18 patients with CDI. Rabphilin-3A was expressed in posterior pituitary and hypothalamic vasopressin neurons but not anterior pituitary. CONCLUSIONS: These results suggest that rabphilin-3A is a major autoantigen in LINH. Autoantibodies to rabphilin-3A may serve as a biomarker for the diagnosis of LINH and be useful for the differential diagnosis in patients with CDI.
Subject(s)
Adaptor Proteins, Signal Transducing/immunology , Autoantibodies/blood , Diabetes Insipidus, Neurogenic/immunology , Nerve Tissue Proteins/immunology , Vesicular Transport Proteins/immunology , Adaptor Proteins, Signal Transducing/metabolism , Adult , Animals , Autoantigens/immunology , Autoimmune Diseases/blood , Autoimmune Diseases/immunology , Autoimmune Diseases/metabolism , Diabetes Insipidus, Neurogenic/blood , Diabetes Insipidus, Neurogenic/diagnosis , Diabetes Insipidus, Neurogenic/metabolism , Diagnosis, Differential , Female , HEK293 Cells , Humans , Lymphocytes/immunology , Male , Nerve Tissue Proteins/metabolism , Pituitary Gland, Posterior/immunology , Pituitary Gland, Posterior/metabolism , Rats , Rats, Sprague-Dawley , Vesicular Transport Proteins/metabolism , Young Adult , Rabphilin-3AABSTRACT
Isolated adrenocorticotropin deficiency (IAD) is characterized by low or absent adrenocorticotropic hormone (ACTH) production. IAD is presumed to be caused in part by an autoimmune mechanism, and several lines of evidence have suggested the presence of anti-pituitary antibodies in IAD. However, the exact autoantigens remain unknown. The present study was designed to identify the autoantigen(s) in IAD using chromatography-tandem mass spectrometry (LC-MS/MS) analysis. Rat anterior pituitary lysate was subjected to SDS-PAGE, and immunoblotting was performed using the sera from two patients with IAD and from a healthy subject. The bands detected by the patient serum samples, but not by the healthy subject sample, were excised, in-gel digested using trypsin, and subjected to LC-MS/MS analysis. On immunoblots, a 51-kDa band in the insoluble pellet was detected by the sera from the IAD patients but not from the healthy subject. Mass spectrometric analysis revealed the 51-kDa band contained Rab guanine nucleotide dissociation inhibitor (GDI) alpha. Consistent with the mass spectrometric analysis, a recombinant full-length human Rab GDI alpha was recognized by the two IAD patient samples but not by the healthy subject sample using immunoblotting. In total, anti-Rab GDI alpha antibodies were detected in serum samples from three of five patients with IAD (60%) but were absent in 5 healthy subjects. In addition, Rab GDI alpha was expressed in the anterior pituitary. In conclusion, it appears that Rab GDI alpha is a candidate autoantigen involved in IAD, and that anti-Rab GDI alpha antibodies are present predominantly in patients with IAD.
Subject(s)
Adrenocorticotropic Hormone/deficiency , Autoantibodies/analysis , Autoantigens/metabolism , Autoimmune Diseases/metabolism , Autoimmunity , Endocrine System Diseases/metabolism , Genetic Diseases, Inborn/metabolism , Guanine Nucleotide Dissociation Inhibitors/metabolism , Hypoglycemia/metabolism , Pituitary Gland, Anterior/metabolism , Adrenocorticotropic Hormone/blood , Adrenocorticotropic Hormone/immunology , Adrenocorticotropic Hormone/metabolism , Adult , Aged , Animals , Antibody Specificity , Autoantigens/chemistry , Autoantigens/genetics , Autoimmune Diseases/blood , Autoimmune Diseases/immunology , Endocrine System Diseases/blood , Endocrine System Diseases/immunology , Female , Genetic Diseases, Inborn/blood , Genetic Diseases, Inborn/immunology , Guanine Nucleotide Dissociation Inhibitors/chemistry , Guanine Nucleotide Dissociation Inhibitors/genetics , Humans , Hypoglycemia/blood , Hypoglycemia/immunology , Japan , Male , Middle Aged , Molecular Weight , Peptide Mapping , Pituitary Gland, Anterior/immunology , Rats, Sprague-Dawley , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Sequence Homology, Amino Acid , Specific Pathogen-Free OrganismsABSTRACT
Overly rapid correction of chronic hyponatremia can cause osmotic demyelination syndrome (ODS). Minocycline protects ODS associated with overly rapid correction of chronic hyponatremia with hypertonic saline infusion in rats. In clinical practice, inadvertent rapid correction frequently occurs due to water diuresis, when vasopressin action suddenly ceases. In addition, vasopressin receptor antagonists have been applied to treat hyponatremia. Here the susceptibility to and pathology of ODS were evaluated using rat models developed to represent rapid correction of chronic hyponatremia in the clinical setting. The protective effect of minocycline against ODS was assessed. Chronic hyponatremia was rapidly corrected by 1 (T1) or 10 mg/kg (T10) of tolvaptan, removal of desmopressin infusion pumps (RP), or administration of hypertonic saline. The severity of neurological impairment in the T1 group was significantly milder than in other groups and brain hemorrhage was found only in the T10 and desmopressin infusion removal groups. Minocycline inhibited demyelination in the T1 group. Further, immunohistochemistry showed loss of aquaporin-4 (AQP4) in astrocytes before demyelination developed. Interestingly, serum AQP4 levels were associated with neurological impairments. Thus, minocycline can prevent ODS caused by overly rapid correction of hyponatremia due to water diuresis associated with vasopressin action suppression. Increased serum AQP4 levels may be a predictive marker for ODS.
Subject(s)
Antidiuretic Hormone Receptor Antagonists/toxicity , Benzazepines/toxicity , Demyelinating Diseases/prevention & control , Diuresis/drug effects , Hyponatremia/therapy , Minocycline/pharmacology , Neuroprotective Agents/pharmacology , Saline Solution, Hypertonic/toxicity , Therapeutics/adverse effects , Animals , Aquaporin 4/blood , Astrocytes/drug effects , Astrocytes/metabolism , Astrocytes/pathology , Behavior, Animal/drug effects , Biomarkers/blood , Brain/drug effects , Brain/metabolism , Brain/pathology , Brain/physiopathology , Chemokines/genetics , Chemokines/metabolism , Cytokines/genetics , Cytokines/metabolism , Cytoprotection , Deamino Arginine Vasopressin , Demyelinating Diseases/blood , Demyelinating Diseases/chemically induced , Demyelinating Diseases/genetics , Demyelinating Diseases/pathology , Demyelinating Diseases/psychology , Disease Models, Animal , Hyponatremia/blood , Hyponatremia/chemically induced , Hyponatremia/physiopathology , Intracranial Hemorrhages/chemically induced , Intracranial Hemorrhages/prevention & control , Male , Matrix Metalloproteinases/genetics , Matrix Metalloproteinases/metabolism , Osmosis , Rats, Sprague-Dawley , Saline Solution, Hypertonic/administration & dosage , Sodium/blood , Time Factors , Tolvaptan , Water-Electrolyte Balance/drug effectsABSTRACT
Although various formulas predicting plasma sodium level ([Na]) are proposed for correction of hyponatremia, it seems that an anticipated [Na] frequently exceeds or falls below the measured [Na], especially in syndrome of inappropriate antidiuretic hormone secretion (SIADH). The causative factors of the fluctuation have never been investigated clearly. The aim of this study was to identify the determining factors for accurate prediction of [Na] by comparing data from previously proposed formulas and a novel osmotic compartment model (O-C model). The O-C model, which simulates the amounts of osmoles in extracellular and intracellular fluids, can estimate resultant osmotic water shift (OWS) and [Na]. The accuracy of representative formulas was verified in a point-to-point study using blood and urine samples obtained every 4 hours from 9 patients. Among 161 measurement points, a large fluctuation of urine volume and urine sodium level was observed. The gap between anticipated and measured [Na] in the widely used Adrogue-Madias formula was -0.5 ± 0.1 mEq/L/4 h (mean ± standard error), showing a marked tendency to underestimate [Na]. The gap in the O-C model including OWS was 0.1 ± 0.1 mEq/L/4 h, and that in the O-C model eliminating OWS was 1.9 ± 0.2 mEq/L/4 h, indicating that measurement of urine output and estimation of resulting OWS are essential for a superior prediction of [Na] in SIADH. A simulation study with the O-C model including OWS unveiled a distinctive correction pattern of [Na] dependent on the urine volume and urine sodium level, providing a useful choice for the proper type and rate of infusion.
Subject(s)
Inappropriate ADH Syndrome/physiopathology , Sodium/blood , Aged , Aged, 80 and over , Blood Chemical Analysis , Female , Humans , Hyponatremia/etiology , Hyponatremia/urine , Male , Middle Aged , Models, Theoretical , Osmosis , Sodium/metabolism , Sodium/urine , UrinationABSTRACT
Aceruloplasminemia is a rare autosomal recessive disease first reported by Miyajima et al. (Neurology 37: 761-767, 1987); it is clinically characterized by diabetes mellitus, retinal degeneration and neurological abnormalities, such as cerebellar ataxia, extrapyramidal signs and dementia. Aceruloplasminemia is caused by mutations in the ceruloplasmin gene, which results in the absence of serum ceruloplasmin and iron overload in the brain, liver, pancreas and other organ tissues. However, little is known about endocrine diseases associated with aceruloplasminemia. We report herein a case of aceruloplasminemia accompanied by central diabetes insipidus and hypothalamic hypothyroidism.
Subject(s)
Diabetes Insipidus, Neurogenic/diagnosis , Hypothalamic Diseases/diagnosis , Hypothyroidism/diagnosis , Adult , Ceruloplasmin/deficiency , Diabetes Insipidus, Neurogenic/complications , Humans , Hypothalamic Diseases/complications , Hypothyroidism/complications , Iron Metabolism Disorders/complications , Iron Metabolism Disorders/diagnosis , Male , Neurodegenerative Diseases/complications , Neurodegenerative Diseases/diagnosisABSTRACT
A 70-year-old woman who was diagnosed with multiple myeloma underwent chemotherapy. Three months after beginning chemotherapy, she was readmitted to the hospital because of fever and hepatopathy. Her elevated Epstein-Barr virus (EBV) antibody levels showed that the hepatopathy was caused by reactivation of EBV. On the 18th hospital day, the levels of fasting plasma glucose (FPG; 451 mg/dL) and pancreatic enzymes were suddenly elevated. Elevation of HbA1c level (6.4%) was slight, as compared with that of the FPG level. Arterial blood gas analysis showed metabolic acidosis and diabetic ketoacidosis was suspected. The serum C-peptide level was below the detectable limit both before and after glucagon load, thereby suggesting an insulin-dependent state. These features were identical to the features for fulminant type 1 diabetes mellitus. The levels of EBV anti-viral capsid antigen immunoglobulin M decreased, and the clinical course was identical to that associated with reactivation of EBV infection. (J Diabetes Invest, doi: 10.1111/j.2040.1124.2010.00061.x, 2010).